SanegeneBio's SGB-9768 Cuts Proteinuria Up to 74.1% in Phase 2 Kidney Disease Trial
Start here
At ASN Kidney Week 2026, SanegeneBio presented interim results from the SGB-9768-003 Phase 2 study in kidney diseases. Among 39 patients completing week-24 follow-up, urine protein-to-creatinine ratio (UPCR) fell from baseline by 58.6% to 74.1%. Reductions were 58.6% in the 300 mg IgAN group, 74.1% in the 600 mg IgAN group, and 63.5% in the C3G/primary IC-MPGN group. Mean serum C3 dropped more than 92% by week 4 and alternative pathway activity was inhibited by more than 95%, with both effects sustained through week 24. The interim data support SGB-9768's complement-directed mechanism across IgAN and C3G/primary IC-MPGN populations; full Phase 2 results and later-stage development remain outstanding.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comSanegeneBio Reports Phase 2 Interim Results for SGB-9768 in Kidney Diseases, UPCR Down 58.6% to 74.1% at Week 24
SanegeneBio presented interim results from the SGB-9768-003 Phase 2 study at ASN Kidney Week 2026, with 39 patients completing the week-24 follow-up and UPCR reductions from baseline of 58.6% to 74.1%. The 300 mg IgAN, 600 mg IgAN, and C3G/primary IC-MPGN groups declined 58.6%, 74.1%, and 63.5%, respectively. Mean serum C3 fell more than 92% by week 4 and alternative pathway activity was inhibited by more than 95%, with both effects sustained through week 24.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 23 09:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.